drugset / Trial / NCT04506905

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

NCT04506905

Phase 1 Completed 63 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, 2-part clinical study of the safety, tolerability and pharmacokinetics of alternate elpipodect titration regimens. Part 1 assessed multiple dose once-daily titration regimens of elpipodect in young adult participants with schizophrenia. Part 2 assessed multiple once-daily doses of elpipodect in elderly participants with schizophrenia and healthy elderly participants.

Timeline

Start
2020-08-28
Primary completion
2022-03-22
Completion
2022-03-22

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-8189 Small molecule 24 mg Oral

Indications